Equities analysts predict that Sophiris Bio Inc (NASDAQ:SPHS) will post earnings per share of ($0.08) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sophiris Bio’s earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.11). Sophiris Bio reported earnings of ($0.11) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 27.3%. The firm is scheduled to issue its next earnings results on Monday, May 13th.
On average, analysts expect that Sophiris Bio will report full year earnings of ($0.28) per share for the current financial year, with EPS estimates ranging from ($0.31) to ($0.25). For the next fiscal year, analysts forecast that the company will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.73) to ($0.33). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Sophiris Bio.
Several research firms have recently weighed in on SPHS. HC Wainwright cut their target price on shares of Sophiris Bio from $10.00 to $3.50 and set a “buy” rating for the company in a report on Thursday, March 14th. Piper Jaffray Companies cut their target price on shares of Sophiris Bio to $5.00 and set an “overweight” rating for the company in a report on Wednesday, March 13th. Maxim Group set a $6.00 target price on shares of Sophiris Bio and gave the company a “buy” rating in a report on Monday, December 17th. Finally, ValuEngine raised shares of Sophiris Bio from a “hold” rating to a “buy” rating in a report on Thursday, December 13th.
Shares of NASDAQ:SPHS traded down $0.04 during trading on Tuesday, hitting $1.08. 241,488 shares of the stock traded hands, compared to its average volume of 143,754. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 2.93. Sophiris Bio has a 52-week low of $0.75 and a 52-week high of $4.05.
Large investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in shares of Sophiris Bio during the 4th quarter valued at approximately $30,000. Hikari Power Ltd increased its holdings in Sophiris Bio by 18.2% in the 4th quarter. Hikari Power Ltd now owns 200,900 shares of the biopharmaceutical company’s stock worth $167,000 after acquiring an additional 30,900 shares in the last quarter. Geode Capital Management LLC increased its holdings in Sophiris Bio by 14.9% in the 4th quarter. Geode Capital Management LLC now owns 243,523 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 31,579 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Sophiris Bio by 293.0% in the 2nd quarter. Northern Trust Corp now owns 80,600 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 60,092 shares in the last quarter. 8.60% of the stock is owned by hedge funds and other institutional investors.
Sophiris Bio Company Profile
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.